JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Srikakulam, R.
Right arrow Articles by Winkelmann, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Srikakulam, R.
Right arrow Articles by Winkelmann, D. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 38, 27265-27273, September 17, 1999


Myosin II Folding Is Mediated by a Molecular Chaperonin*

Rajani Srikakulam and Donald A. WinkelmannDagger

From the Department of Pathology and Laboratory Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey 08854

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The folding pathway of the heavy meromyosin subfragment (HMM) of a skeletal muscle myosin has been investigated by in vitro synthesis of the myosin heavy and light chains in a coupled transcription and translation assay. Analysis of the nascent translation products for folding intermediates has identified a major intermediate that contains all three myosin subunits in a complex with the eukaryotic cytosolic chaperonin. Partially folded HMM is released from this complex in an ATP-dependent manner. However, biochemical and functional assays reveal incomplete folding of the myosin motor domain. Dimerization of myosin heavy chains and association of heavy and light chains are accomplished early in the folding pathway. To test for other factors necessary for the complete folding of myosin, a cytoplasmic extract was prepared from myotubes produced by a mouse myogenic cell line. This extract dramatically enhanced the folding of HMM, suggesting a role for muscle-specific factors in the folding pathway. We conclude that the molecular assembly of myosin is mediated by the eukaryotic cytosolic chaperonin with folding of the motor domain as the slow step in the pathway.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Muscle myosin, the prototype of the myosin II family, is a large asymmetric, multidomain protein composed of six polypeptides: two heavy chains of molecular mass 220 kDa and two pairs of non-identical light chains of molecular mass 17-23 kDa. The amino-terminal ~845 residues of each heavy chain associates with two different light chains to form an elongated, globular domain (S1)1 that contains the sites for ATP hydrolysis and actin binding (1). This domain is sufficient for powering the movement of actin filaments. The carboxyl-terminal ~1100 residues of the myosin heavy chains associate to form an alpha -helical coiled-coil rod essential for myosin filament assembly.

Crystallographic determination of the S1 structure and electron microscopic studies have contributed a great deal to our understanding of the structure of the molecule and mapping of the functional sites (2, 3). The myosin catalytic domain is a compact structure formed by the amino-terminal ~765 residues of the heavy chain. The ATP-binding pocket in this domain is formed by a structural motif that is shared with the kinesin family of microtubule-based motors and with G-proteins that are involved in signal transduction (4). The core motif is a seven-strand mostly parallel beta -sheet that is flanked by three alpha -helices on each side. A large insertion into the core motif forms the actin binding surface and distinguishes the myosin structure from kinesin and the G-proteins. Extending from the myosin catalytic domain is an 85-Å-long alpha -helix that is stabilized by the binding of two myosin light chains. This domain is believed to act as a lever arm to amplify and transmit structural changes in the catalytic domain into relative motion of actin and myosin (5). The light chain binding helix terminates in a proline that starts the long rod domain.

Despite the extensive knowledge about the structure of the molecule, our understanding of the folding pathway is limited. It must involve the folding of catalytic domain, association of the light chains, and dimerization of the long COOH-terminal alpha -helical segment of the two heavy chains. Myosin light chains and various rod subfragments can be synthesized in bacteria and fold properly, suggesting an autonomous folding pathway (6-8). However, myosin head fragments of various lengths expressed in bacteria are functionally inactive, suggesting that eukaryotic factors acting post-translationally may be required for folding (9).

It is now well established that, although the folding of a protein is largely directed by its amino acid sequence, this process is often mediated by accessory proteins known as molecular chaperones (10, 11). Chaperonins are a class of molecular chaperones that consist of multisubunit toroidal ring structures and are believed to mediate folding by providing a sequestered environment within the ring (12). The chaperonin containing TCP-1 (CCT) present in the eukaryotic cytosol, is a relatively new member of this class (13). It has been implicated in the folding of actin; alpha , beta , and gamma  tubulins; and an actin-related protein (14-18). The folding pathways of actin and tubulin are now understood in great detail due to the discovery that the folding of these proteins is mediated by CCT in the eukaryotic cytosol (19).

Several recent studies have helped to elucidate the genetic, structural and mechanistic aspects of this chaperonin (12, 13, 20, 21). One intriguing anomaly of CCT-mediated folding is the apparently limited target range in comparison to the bacterial analog GroEL (22). However, a more general role for CCT in protein folding is slowly emerging. In addition to the substrates already mentioned, CCT has recently been shown to mediate the folding of the G-protein, Galpha -transducin (21). CCT is also thought to be involved in the organization of the neuronal cytoskeleton and in hepatitis virus capsid assembly (13).

Here we present an analysis of the folding of the heavy meromyosin subfragment (HMM) of myosin synthesized in a rabbit reticulocyte lysate and show that it is mediated by CCT. Dimerization of heavy chains and the association of heavy and light chains are accomplished efficiently. However, HMM synthesized in this system lacks a properly folded motor domain, and is defective in its actin binding properties. Thus, in addition to the protein folding machinery available in the reticulocyte lysates, myosin may require additional folding factors. The expression systems that are widely used for non-muscle myosin (5, 23) and smooth (24) and, to a more limited extent, cardiac muscle myosin (25) have not proven useful for the expression of fast skeletal muscle myosin. On the other hand, the mouse myogenic cell line C2C12 has been successfully used for the expression of this myosin isoform (26). Based on this, we hypothesized that the folding of skeletal muscle myosin may require specific folding factors present in muscle cells. Folding assays performed in the presence of C2C12 cytoplasmic extracts, yield significantly more "native-like" protein. This molecular form of HMM displays enhanced folding of the motor domain, improved actin binding properties, and stabilization of the coiled-coil alpha -helix.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Coupled Transcription/Translation-- The skeletal muscle heavy meromyosin expression plasmid was constructed from a full-length chimeric cDNA corresponding to the epitope tagged embryonic chicken myosin cDNA previously described (26). The HMM cDNA encodes amino acids 1-1293 of myosin and was inserted between the EcoRI and XbaI cloning sites of pGEM4 (Promega Corp., Madison, WI) with the 5' end of the cDNA adjacent to the plasmid Sp6 promoter (p4HMMa). The chicken fast skeletal muscle myosin light chain 2 cDNA (GenBank accession no. M11030) was provided by Dr. Fernando Reinach (27), and LC3 cDNA was provided by Dr. Bruce Patterson (GenBank accession no. J00888). The LC2 and LC3 cDNAs were cloned adjacent to an SP6 promoter into plasmids pGEM3 and p73 (Promega Corp.), respectively (p3mLC2 and p73mLC3). The myosin coding regions of the expression constructs were confirmed by DNA sequencing.

The expression plasmids for the HMM heavy chain and the essential (LC3) and regulatory (LC2) light chains were expressed by coupled transcription and translation in the TNT lysate system (Promega Corp.). The reactions were performed as per manufacturer's protocol, in the presence 80 µCi/100-µl reaction of [35S]methionine (1175 Ci/mmol; NEN Life Science Products). All translations were carried out at 30 °C for 2 h. The molar ratio of the three myosin expression plasmids was adjusted such that approximately equimolar amounts of myosin heavy and light chains are produced.

Chromatographic Analysis-- Translation reactions (200 µl) containing newly synthesized HMM and light chains were depleted of ATP and exchanged into column buffer by rapid gel filtration on a Sephadex G-50 spin column (Amersham Pharmacia Biotech) equilibrated with 20 mM MES (pH 6.9), 100 mM KCl, 1 mM MgCl2, 0.5 mM EGTA, 2.5% glycerol, 1 mM dithiothreitol (18). The effluent from the Sephadex column was divided into two aliquots. One aliquot was applied directly to a Superose 6 HR 10/30 gel filtration column (Amersham Pharmacia Biotech), equilibrated in the same buffer; the other was incubated with 5 mM Mg2+ATP for an additional 60 min at 30 °C and then applied to the column. The elution characteristics of the 10 mm (inner diameter) × 30-cm-long Superose 6 column (flow rate of 0.25 ml/min) were calibrated using myosin, HMM, myosin S1, and myosin light chains, myoglobin, serum albumin, and other proteins. Column fractions (0.5 ml) were analyzed by scintillation counting and SDS-polyacrylamide gel electrophoresis (28). The radioactive myosin heavy and light chains in the column fractions were quantitated by phosphorimaging of the dried SDS gels (Molecular Dynamics, Sunnyvale, CA). To analyze the effect of the S30 extract on folding, Mg2+ATP-depleted samples were supplemented with an equal volume of the S30 fraction (see below), brought to 5 mM Mg2+ATP, and incubated for 60 min at 30 °C. The products were then analyzed by gel filtration chromatography.

For analysis by anion exchange chromatography, a 100-µl translation reaction was eluted on Sephadex G-50 spin column equilibrated with 20 mM MgCl2, 10 mM KCl, 2 mM EGTA, 10 mM Tris-HCl (pH 7.2), 1 mM dithiothreitol (14). The effluent was diluted 5-fold with this buffer and applied to a HR 5/5 Mono-Q column with dimensions 5 mm (inner diameter) × 5 cm (Amersham Pharmacia Biotech). The bound proteins were eluted with a linear gradient of 20-500 mM MgCl2 over 14 min at flow rate of 1 ml/min. Column fractions were collected and analyzed by scintillation counting and SDS-PAGE. The myosin heavy and light chain subunits were analyzed by phosphorimaging of the SDS gels. Fractions from the gel filtration and anion-exchange columns were subjected to SDS-PAGE. The protein gel patterns were transferred to nitrocellulose using a semidry blotting apparatus (29), and the nitrocellulose replicas were probed with mAb 91A, a rat monoclonal antibody against TCP-1alpha subunit (30) (Stressgen Biotechnologies, Victoria, British Columbia, Canada). The immunoreactive species were detected by chemiluminescence (Pierce).

Native and Denaturing Immunoprecipitation-- Native immunoprecipitations were done with a 50-µl translation reaction that was depleted of Mg2+ATP and adjusted to 150 mM NaCl, 10 mM MgCl2, 20 mM HEPES (pH 7.5) by elution from a Sephadex G-50 spin column. The effluent was incubated with 5 mM Mg2+ATPgamma S at 30 °C, for 60 min. After 2-fold dilution with the same buffer containing 0.05% Nonidet P-40 and 0.05% Triton X-100, the sample was divided into three aliquots and incubated with PBS or 5 µg of mAb 23C, a rat monoclonal antibody against TCP-1alpha subunit (17, 30) (Stressgen Biotechnologies), or anti-S1 mAb 4H7.6 (31). Incubations with primary antibodies were carried out for 4-6 h on ice, followed by 2-4 h of incubation with rabbit anti-rat IgG or anti-mouse IgG secondary antibody (Sigma). The secondary antibody was used in 2-fold excess over the primary antibody. The resulting immunocomplexes were absorbed with formaldehyde-fixed Staphylococcus aureus (Immunoprecipitin; Life Technologies, Inc.). The pellets were washed four times with buffer containing 0.1% Triton X-100 and once with PBS and finally extracted into 50 µl of SDS sample buffer and analyzed by SDS-PAGE and autoradiography.

For some experiments, CCT was depleted from the lysates by immuunoabsorption prior to translation. Aliquots of rabbit reticulocyte lysate from the TNT lysate kit were incubated on ice for 60 min, with either mAb 23C or H2O (control). The immunocomplexes were then incubated with Immunoprecipitin for an additional 15 min. The lysates were clarified by centrifugation and used in coupled transcription/translation assays as described above.

Immunoprecipitation of denatured translation products with anti-S1 mAb 4H7.6 and anti-S2 mAb 10F12.3 was done with translation reaction aliquots equilibrated with 150 mM NaCl, 10 mM MgCl2, 20 mM HEPES (pH 7.5), then denatured by diluting with an equal volume of buffer containing 2% SDS and 12 mM beta -mercaptoethanol and boiling for 10 min. After clarification with a brief microcentrifuge spin, samples were diluted with one volume of H2O and eight volumes of buffer containing 1% Triton X-100. Aliquots of the diluted sample were incubated either with buffer or 5 µg of the appropriate antibody. The subsequent processing steps were identical to native immunoprecipitation.

Preparation of Myotube S30 Fraction-- Growth and fusion of C2C12 cells has been previously described in detail (26). Well differentiated myotubes, 3-4 days after fusion, were used to prepare an S30 fraction according to a protocol developed by Moldave and Fischer for Chinese hamster ovary cells (32). Myotubes growing on 100-mm dishes were washed once with 0.035 M Tris-HCl (pH 7.3), 0.15 M NaCl, 0.011 M glucose, and collected into the same buffer by scraping the cell layer. The cell pellet was collected by centrifugation at 3000 × g for 5 min and resuspended in an equal volume of 0.01 M Tris-HCl (pH 7.3), 0.015 M KCl, 0.0015 M magnesium acetate, 6 mM beta -mercaptoethanol. The cells were homogenized by 30-40 strokes in a Dounce glass homogenizer and adjusted to 0.02 M HEPES-KOH (pH 7.3), 0.12 M KCl, 5 mM magnesium acetate, and 6 mM beta -mercaptoethanol. The postmitochondrial fraction was obtained by centrifugation at 30,000 × g for 20 min at 4 °C. The final step of the original protocol was modified to use 0.02 M HEPES-KOH (pH 7.3), 60 mM potassium acetate, 0.5 mM magnesium acetate, and 6 mM beta -mercaptoethanol (S30 buffer). The buffer exchange was performed using G-50 spin columns that were presaturated with old reticulocyte lysate to avoid depletion of ribosomes (33). This buffer system was found to be most compatible with the translation buffer of TNT lysate system and yielded optimum levels of myosin heavy chain in our translations. The gel-filtered S30 fraction was dispensed into 100-µl aliquots, quick-frozen, and stored in liquid nitrogen. Typically, myotubes from 16-20 dishes yielded approximately 2 ml of S30 fraction with an absorbance of 10-12 A260 units/ml. Removal of endogenous mRNA from the S30 fraction was unnecessary since translation in the TNT assay without added exogenous plasmid resulted in background levels of [35S]methionine incorporation.

Limited Proteolysis of the Folding Reactions-- Folding reactions were supplemented with native HMM at 2.5 mg/ml and subjected to limited proteolysis with 25 µg/ml bovine pancreas trypsin (Sigma) at 25 °C. Aliquots were withdrawn at various times, diluted 10-fold into SDS sample buffer and boiled immediately, then subjected to SDS-PAGE analysis followed by immunoblotting with anti-myosin mAb 4H7.6, F59, 1H2.2, and 8G12.5 (31). The proteolytic fragments of nascent HMM were visualized by autoradiography of the immunoblots.

Folding reactions were supplemented with the S30 fraction of a C2C12 myotube extract or an equal volumes of S30 buffer and incubated for an additional 60 min at 30 °C to continue folding. Samples were then supplemented with 2.5 mg/ml native HMM, digested with trypsin, and analyzed as already described. For immunoprecipitation analysis, samples from a 30-min time point were diluted 8-fold into SDS sample buffer and boiled for 10 min. After clarification in a microcentrifuge, the samples were diluted 10-fold with S30 buffer containing 1% Triton X-100. Aliquots of the diluted sample were incubated with either PBS or 10 µg of an anti-myosin mAb (4H7.6, F59, 1H2.2, or 8G12.5) and then analyzed as described above.

Actin Binding Assay-- Translations (50 µl) were performed either in rabbit reticulocyte lysate alone or in lysate supplemented with C2C12 extract, in a 1:10 ratio. The samples were eluted on Sephadex G-50 columns equilibrated with 25 mM imidazole, 25 mM KCl, 4.0 mM MgCl2, 0.2 mM CaCl2, and 1 mM dithiothreitol and supplemented with 0.25-0.30 mg/ml native HMM and 0.25 mg/ml F-actin and incubated for 30 min at 25 °C. The resulting actomyosin complexes were incubated for another 10 min with either 10 µg/ml apyrase, to eliminate ATP (Sigma), or 1 mM Mg2+ATP. Actin and actomyosin complexes were obtained by centrifugation at 100,000 × g for 21 min. The pellets were extracted into 100 µl of SDS sample buffer. The supernatants and pellets were analyzed by SDS-PAGE and autoradiography, for the free and actin-bound HMM.

Preparation of Native Proteins-- Native HMM was prepared by chymotryptic digestion of adult chicken pectoralis major muscle myosin essentially according to Margossian and Lowey (34). Addition of 5 mM MgCl2 prior to digestion was found to increase the yield of HMM. Skeletal muscle actin was prepared from an acetone powder of chicken pectoralis muscle according to Winkelmann et al. (35).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Association of Newly Synthesized HMM with a Molecular Chaperone-- We studied folding of de novo synthesized myosin in an eukaryotic expression assay. The HMM of myosin contains most of the structural and functional domains of myosin, and lacks only the light meromyosin subfragment (LMM). Myosin subfragments lacking LMM are soluble in low ionic strength buffers, making them more amenable for subsequent analysis. Therefore, most of our studies on myosin folding were carried out with the HMM heavy chain. The cDNAs for the HMM heavy chain and myosin light chains were cloned into plasmids adjacent to a bacterial SP6 promoter for expression in a coupled transcription and translation assay. The assay uses purified SP6 RNA polymerase for transcription and a rabbit reticulocyte lysate translation system. The coupled assay efficiently produces the myosin subunits (the 140-, 19-, and 17-kDa polypeptides for HMM, LC2, and LC3, respectively) when the plasmids are mixed (Fig. 1). This permits the analysis of co-expressed nascent subunits for intermediates in the folding pathway. The plasmids for the heavy and light chain were used in a 2.2:1.25:1.0 (p4HMMa:p3mLC2:p73mLC3) molar ratio, in order to achieve comparable levels of synthesis of the three polypeptides. The time course of synthesis shows that full-length HMM heavy chains do not appear until 20 min after the start of the reaction, and reach maximum synthesis after 120 min of translation. On the other hand, light chains begin to accumulate within the first 5 min and quickly reach steady state by 20 min. Typically, a 2-h synthesis results in an incorporation of 10-15% of the added [35S]methionine into protein.


View larger version (94K):
[in this window]
[in a new window]
 
Fig. 1.   Time course of synthesis of HMM heavy chain and light chain subunits in a rabbit reticulocyte lysate coupled transcription/translation assay. Three plasmids (p4HMMa, p3mLC2, and p73mLC3) were mixed in a 2.2:1.25:1.0 molar ratio and added to the TNT lysate with Sp6 RNA polymerase and [35S]methionine. Time points were taken for analysis by SDS-PAGE, autoradiography, and phosphorimaging. The 140-kDa HMM heavy chain, 19-kDa LC2, and 17-kDa LC3 are synthesized together in this assay. The maximum levels of incorporation are achieved in 2 h. The ratio of the plasmids required to achieve comparable levels of expression of the three proteins was determined empirically.

It is now recognized that, although the folding of proteins is directed by their primary sequence, in many instances this process is aided by accessory proteins called molecular chaperones. Chaperonin-mediated folding of proteins involves rapid formation of a binary complex of nascent polypeptides with the chaperonin and a slow Mg2+ATP-dependent release of fully or partially folded protein from this complex (10). Partially folded polypeptides repeat this cycle until folding is complete. In the absence of Mg2+ATP, polypeptides associated with a molecular chaperone often remain arrested in that form. To investigate if a similar mechanism underlies myosin folding, we depleted Mg2+ATP from translations containing nascent HMM subunits and analyzed the products by gel filtration chromatography (Fig. 2). The chromatogram showed a major radioactive peak eluting at 11.25-12.25 ml. Native HMM elutes as a sharp peak at 9.25-9.75 ml with an apparent molecular mass that is higher (>2000 kDa) than the calculated mass (340 kDa) because of its highly asymmetric shape. The elution position of nascent HMM on the gel filtration column suggested a more compact shape or the association of HMM with a reticulocyte lysate protein (Fig. 2a). This molecular form, designated as peak I (pI), accounts for approximately a third of the total radioactivity. Two additional peaks were also observed, one of which corresponds to free light chains, and the other to unincorporated [35S]methionine and [35S]methionyl-tRNA complex (data not shown).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Gel filtration chromatography of nascent HMM. a, Mg2+ATP was depleted before the translation mixture was separated on a Superose 6 gel filtration column. A major radioactive peak (pI) elutes at ~900 kDa (dotted line). SDS-PAGE and phosphoimager analysis of myosin subunits HMM (), LC2 (triangle ) and LC3 (black-triangle) show association of these subunits in the peak fractions. b, when the reaction is incubated with Mg2+ATP before chromatography, there is a decrease in pI radioactivity and the appearance of two new peaks, pII and pIII. c, immunoblotting of column fractions with an anti-TCP-1 mAb 91A detects the 60-kDa, TCP-1alpha subunit in the fractions corresponding to pI in the absence of Mg2+ATP. When samples are incubated with Mg2+ATP before chromatography, there is a reduction in the amount of TCP-1alpha in the pI fractions. There is an increase in TCP-1alpha eluting at ~15 ml corresponding to disassembled oligomers.

The effect of Mg2+ATP on the folding intermediates was shown by incubating an aliquot with 5 mM Mg2+ATP prior to gel filtration. There is a dramatic conversion of pI into two new forms, peak II (pII) and peak III (pIII), after incubation with Mg2+ATP (Fig. 2b). The elution position of pII corresponds to that of the native HMM, whereas pIII elutes in the void volume of the column. Quantitation of heavy and light chains in the different molecular forms showed equimolar ratios of these subunits in pI and pII, whereas the ratio in pIII is skewed toward the heavy chain.

Recent evidence indicates that the folding of actin, tubulin and related proteins in the eukaryotic cytosol is mediated by CCT (14, 16, 17). To investigate if this chaperonin is also involved in myosin folding, the peak fractions were probed with mAb 91A (30), an antibody against TCP-1 alpha  subunit (Fig. 2c). This antibody detected a 60-kDa polypeptide in the fractions corresponding to pI, suggesting that pI may be a complex of HMM with CCT. In the presence of Mg2+ATP, release of HMM into pII and pIII was accompanied by a decrease of TCP-1 immunoreactivity in pI. In addition, TCP-1 was also detected in pIII, but not pII. In both the cases, CCT subunits were also found in lower molecular mass fractions (120-60 kDa), suggesting disassembly of the CCT complex (36, 37).

It is possible that the co-elution of TCP-1 with HMM in the gel filtration experiment is a consequence of similarities in their size, rather than a true association. To examine this possibility, the translation products were resolved on an anion-exchange column, using a buffer system developed by Gao et al. (14) for the purification of CCT from reticulocyte lysate. When a translation reaction depleted of Mg2+ATP was applied to a mono-Q column, more than 90% of the translated protein eluted as a single peak at ~180 mM salt (Fig. 3). Native HMM under these conditions eluted at 236 mM salt. Immunoblotting of the column fractions with mAb 91A detected TCP-1 in the radioactive peak. Quantitation of HMM heavy and light chains in this peak showed that they are present in 1:1:1 stoichiometry. The co-elution of HMM with TCP-1 under two very different conditions strongly argues for an association of HMM with CCT. The co-elution of the myosin heavy and light chains in both column experiments also indicates that this association occurs early in the myosin folding pathway.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 3.   Anion exchange chromatography of nascent HMM. A translation mix depleted of Mg2+ATP was applied to a Mono Q column and eluted with a linear gradient of 20-300 mM MgCl2. The profile shows a major radioactive peak eluting at ~180 mM MgCl2. SDS-PAGE and phosphoimager analysis (inset) of HMM (), LC2 (triangle ), and LC3 (black-triangle) show the association of HMM with LCs. Immunoblotting of the column fractions (inset) with mAb 91A shows the co-elution of TCP-1alpha with nascent HMM. The MgCl2 concentration and the elution position of native HMM are indicated along the top of the figure.

Association of HMM with CCT was confirmed by immunoprecipitation of HMM-CCT complex with another anti-TCP-1 mAb, 23C. This antibody performs better than mAb 91A in immunoprecipitation assays (17). Release of polypeptides from CCT requires hydrolysis of ATP. Thus, in the presence of ATPgamma S, a non-hydrolyzable analogue of ATP, polypeptides should be arrested in the complex. In control experiments performed with reticulocyte lysates in the absence of HMM, immunoprecipitation of CCT by mAb 23C was found to be most effective in the presence of Mg2+ATPgamma S and least effective in the complete absence of Mg2+ATP (data not shown). Therefore, our native immunoprecipitations were performed in the presence of Mg2+ATPgamma S. Nascent HMM co-immunoprecipitated by mAb 23C under these conditions, although the efficiency of immunoprecipitation was not as dramatic as with an anti-S1 antibody (Fig. 4). Quantitation by scintillation counting showed that the amount of HMM present in the mAb 23C immunocomplexes was approximately 3 times above the control, and the increase was consistent in independent experiments. Thus, three lines of evidence point to a transient association of nascent HMM with CCT.


View larger version (76K):
[in this window]
[in a new window]
 
Fig. 4.   Immunoprecipitation of HMM-CCT complex with anti-TCP-1 mAb. A translation mix depleted of Mg2+ATP was incubated with 5 mM Mg2+ATPgamma S and mAb 23C (anti-TCP-1) under native conditions. The immune complexes were isolate with immunoprecipitin, and the supernatant (s) and precipitate (p) fractions were analyzed by SDS-PAGE and autoradiography to detect HMM. The samples incubated with PBS (No 1°) and anti-S1 mAb (anti-S1; 4H7.6) serve as negative and positive controls, respectively.

The requirement of CCT for HMM folding was addressed by an immunodepletion experiment. Translations were done in lysates that were partially depleted of CCT by immunoabsorption, and the translation products were analyzed by gel filtration chromatography for the presence of a binary complex. To affect this analysis, aliquots of reticulocyte lysate were incubated with mAb 23C or with H2O (control) and the immune complexes removed with Immunoprecipitin. Western blot analysis with mAb 91A showed significantly lower levels of CCT in the lysates treated with 23C, in comparison to the control lysates (Fig. 5a). The overall level of protein synthesis was not affected by the removal of CCT, as judged by the concentration of HMM in unfractionated translation reactions. However, lysates depleted of CCT yielded significantly lower levels of the pI intermediate as compared with the control (Fig. 5b) or untreated lysates (Fig. 2a). This result strongly argues that pI is a complex of HMM with CCT. The overall recovery of nascent HMM from the depleted lysates was very poor. The likely explanation for poor recovery is that, in the absence of CCT, the nascent polypeptides become "sticky" as a consequence of exposed hydrophobic sites; such polypeptides are easily lost during processing by binding irretrievably to plastic and glassware. One might expect that nascent HMM would be trapped as a complex with other lysate factors in the absence of CCT, and would appear as new peaks in the gel filtration assay. Lack of such new intermediates implies that HMM-CCT complex is an essential and early precursor in the folding process and that removal of CCT cannot be compensated by other lysate factors.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 5.   Aliquots of reticulocyte lysates were depleted of CCT by immunoabsorption with anti-TCP-1alpha mAb, 23C, and compared with buffer-treated control lysate. a, Western blots reveal a significant depletion of CCT in the antibody-treated lysate (Ab) versus untreated (u) and buffer-treated (B) lysates. Samples were resolved on an 8% gel and probed with mAb 91A. The untreated lysate was loaded five times in excess of the antibody-treated (Ab) and buffer-treated (B) lysates. Autoradiography of the translation products resolved on SDS-PAGE shows that the levels of HMM synthesis in immunoabsorbed and buffer-treated lysates are comparable. b, the gel filtration elution profile of the lysate depleted of CCT () compared with the control buffer-treated (open circle ) lysate shows a remarkable decrease in the pI intermediate. There is also a significant decrease in the recovery of radioactivity from the CCT-depleted lysate despite comparable levels of total synthesis.

We conclude from these observations that folding of HMM in rabbit reticulocyte lysate occurs via the formation of a complex with CCT (pI); it is released from this complex into two different conformational states (pII and pIII) in an ATP-dependent manner. One of the intermediates, pII, behaves as a native protein in the gel filtration assay and does not reassociate with CCT. The second intermediate, pIII, elutes as a high molecular mass intermediate and is recaptured by CCT. The association of heavy and light chain subunits is accomplished early in the folding pathway, since light chains are found in all the intermediates.

Characterization of the Folding Intermediates-- Resistance to proteolytic digestion is a hallmark of properly folded proteins, so limited proteolysis is often used to investigate the presence of folded domains. The myosin motor domain has been studied extensively using proteolysis. Limited proteolysis of S1 by trypsin produces three distinct fragments of molecular mass 25, 50, and 20 kDa (38). The molecular basis of this cleavage pattern is clear from the structure of myosin S1 (3). The cleavage occurs in two extended, flexible loops that are sensitive to a wide range of proteases. The formation of the fragments produced by cleavage of the loops can be considered a measure of myosin folding.

The digestion patterns of native and nascent HMM were compared by limited proteolysis of a mixture of these two proteins (Fig. 6). Native HMM produced the characteristic 50-, 25-, and 20-kDa fragments from the motor domain and a 52-kDa fragment corresponding to S2. These fragments were identified against the background of reticulocyte lysate proteins by probing Western blots of the digest with mAbs that recognize these fragments. Autoradiography of the blots revealed that nascent HMM in the same digestion mix generated fragments of 68, 55, 45, and 30 kDa. Thus, nascent HMM displays discrete protease-resistant fragments, indicative of folding; however, the lack of overlap between the nascent and native fragments indicates a significant difference in the extent of folding of the nascent HMM.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 6.   Limited proteolysis of nascent HMM to analyze the extent of folding. A mixture of native HMM and nascent HMM was digested with trypsin. Samples withdrawn at 0, 5, and 30 min were analyzed by SDS-PAGE. Native panels represent immunoblots of the gels probed with anti-25-kDa (4H7.6), anti-50-kDa (F59), anti-20-kDa (1H2.2), and anti-S2 (8G12.5) (31, 35). The arrows indicate the positions of these fragments. The panels labeled Nascent are autoradiographs of the immunoblots and show the radioactive proteolytic fragments of nascent HMM. Nascent HMM displays 68-, 55-, 45-, and 30-kDa fragments in contrast to the characteristic 50-, 25-, and 20-kDa fragments of the native protein. The distinct digestion pattern of nascent HMM is indicative of partial folding.

Native HMM molecules consist of dimers of the heavy chains associated through a long alpha -helical coiled-coil interaction. We analyzed the folding of S2 region using anti-S2 mAb 10F12.3, a conformation-sensitive antibody that preferentially binds S2 in its coiled-coil conformation (39, 40). In Western blot analysis, this antibody reacts strongly with native HMM resolved on native gels, but shows very weak recognition of the same fragment blotted from denaturing gels (data not shown). The immunoprecipitation of nascent HMM was analyzed with this antibody under native and denaturing conditions (Fig. 7). Nascent HMM formed stable immunocomplexes with mAb 10F12.3 under native conditions, suggesting that the S2 region is in the native dimer conformation. Quantitation of HMM associated with 10F12.3 under native conditions suggests that at least 30% of the nascent population exist as dimers. The absence of significant precipitation of HMM by 10F12.3 under denaturing conditions confirms that this antibody is sensitive to conformation. The mAb used as a positive control in this assay, 4H7.6, is insensitive to conformation. Hence, the higher efficiency of HMM immunoprecipitation is a result of the fact that 4H7.6 binds the myosin heads irrespective of dimerization or folding.


View larger version (73K):
[in this window]
[in a new window]
 
Fig. 7.   Investigation of nascent S2 domain using a conformation-sensitive antibody, mAb 10F12.3. a, a translation mix was depleted of Mg2+ATP and immunoprecipitated with anti-S2 mAb (anti-S2; 10F12.3) under native and denaturing conditions. The samples incubated with PBS (No 1°) and mAb 4H7.6 (anti-S1) serve as negative and positive controls, respectively. The supernatant (s) and pellet (p) fractions for each case were analyzed by SDS-PAGE. The presence of nascent HMM in 10F12.3 immunocomplexes only under native conditions is indicative of S2 folding.

Based on the results of the biochemical and immunological analysis of nascent HMM, we conclude that it lacks a properly folded motor domain; however, the S2 region assumes the native dimer conformation in at least a third of the nascent molecules.

Folding Assays in the Presence of C2C12-S30 Fraction-- These data show that CCT mediates the folding of nascent HMM in reticulocyte lysates; however, association of HMM with CCT results in the partial folding of the molecule. This prompted a search for other factors necessary for the complete folding of HMM. The mouse cell line, C2C12, is a well characterized myogenic cell line that efficiently produces muscle myosin (26). Fusion of near-confluent C2C12 myoblasts into myotubes results in a dramatic up-regulation of myosin synthesis. Myosin expressed in these cells folds completely, assembles into striated myofibrils that actively contract, and when isolated it is fully functional in vitro (26). Therefore, we reasoned that C2C12 myotubes should be a good source of potential factors necessary for myosin folding.

An S30 fraction was prepared from C2C12 myotubes to study its effect on the folding of HMM synthesized in rabbit reticulocyte lysates. Translation reactions depleted of Mg2+ATP were incubated with C2C12 cytoplasmic extract and 5 mM Mg2+ATP, and the intermediates were separated on a gel filtration column. The major product in this case was pII, eluting at the position of native HMM (Fig. 8). The quantitation of radioactive heavy and light chains in pII showed equimolar ratios of these subunits. Thus, incubation with the S30 fraction from myotubes dramatically improved conversion of pI to pII. We considered the possibility that this result may simply be due to a free light chain pool present in the extract. Folding reactions supplemented with purified light chains, at a concentration above that in our extract, yielded the same results as unsupplemented reactions (data not shown).


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 8.   C2C12 myotube extracts enhance folding of nascent HMM. A translation mix depleted of Mg2+ATP was incubated with an S30 fraction from C2C12 myotubes, and the products were resolved on Superose 6 column. The major radioactive peak in this case corresponds to pII of Fig. 2b. SDS-PAGE and PhosphorImager analysis of myosin subunits HMM (), LC2 (triangle ), and LC3 (black-triangle) show association of these subunits in an approximately 1:1:1 ratio.

Limited proteolysis of nascent HMM folded in the S30 supplemented lysate confirmed the gel filtration experiment. Native HMM was added to nascent HMM produced in the reactions supplemented with C2C12 extract, and the mixture was digested with trypsin. The digests of supplemented folding reactions showed a stable 75-kDa fragment, which co-migrates with the same sized fragment derived from native HMM (Fig. 9a). In addition, the supplemented digests showed a 68-kDa fragment, similar to that seen in the unsupplemented digests (Fig. 6). Immnuoprecipitation of the proteolytic fragments with anti-myosin antibodies, showed that an anti-25-kDa mAb (4H7.6) and an anti-50-kDa mAb (F59) both recognize the 75-kDa fragment in digests of the supplemented folding reaction (Fig. 9b), indicating that it is a composite of the NH2-terminal 25- and 50-kDa fragments of the myosin motor domain. The anti-S2 mAb (8G12.5) recognized the 68-kDa fragment in both digests. This fragment probably arises from the S2 region together with the 20-kDa fragment of myosin S1. The presence of this fragment in both digests confirms our previous result regarding S2 dimerization. However, the recovery of this fragment from the supplemented digests was significantly higher, suggesting that the S30 extract further stabilizes the S2 region.


View larger version (93K):
[in this window]
[in a new window]
 
Fig. 9.   Analysis of nascent HMM produced in the presence of S30 extract. a, nascent HMM from folding reactions with and without the S30 extract was mixed with native HMM and digested with trypsin for various times. The fragments were analyzed by SDS-PAGE and autoradiography. Panels labeled Native show the Coomassie Blue staining of the native HMM fragments, and those labeled Nascent are autoradiographs revealing nascent fragments. In reactions containing the S30 extract (+), nascent HMM produces a stable 75-kDa fragment, which co-migrates with the same sized fragment produced by native HMM. In addition, it also shows two fragments in the size range 68-66 kDa, which corresponds to the 68-kDa fragment produced from nascent HMM even without the S30 extract (-). b, the proteolytic fragments from folding reactions with (+) or without (-) the S30 extract were immunoprecipitated with antibodies against the 25-, 50-, and 20-kDa fragments of myosin S1 and the S2 mAb 8G12.5 and the precipitates were analyzed by SDS-PAGE. The anti-25-kDa and anti-50-kDa mAbs recognize a 75-kDa fragment in digests of the C2C12 supplemented reactions. The anti-S2 antibody recognized a 68-kDa fragment found in digests of both folding reactions; however, the amount of this fragment recovered from S30 supplemented reaction is significantly higher. c, translation reactions were performed in the absence (-S30) and presence of S30 extract (+S30). Native HMM and F-actin were added to the samples, and the resulting actomyosin complexes were incubated either with apyrase to deplete ATP (-ATP) or with Mg2+ATP added (+ATP). The F-actin was collected by centrifugation, and the supernatant (s) and pellet (p) fractions were analyzed by SDS-PAGE for the free and actin-bound HMM. Total HMM produced in the translation reactions is indicated (t). Nascent HMM produced in the reticulocyte lysate alone (-) binds actin poorly irrespective of ATP. In contrast, HMM produced in the lysate supplemented with extract binds actin efficiently in the absence of ATP. Addition of ATP results in a partial release of this species from actin.

Functional Assay-- Finally, we tested the effect of the S30 extract on the functional properties of nascent HMM. Generation of motion involves cyclic binding and release of actin filaments by myosin. In the absence of Mg2+ATP myosin binds actin with high affinity; the binding of Mg2+ATP to myosin induces conformational changes leading to a low affinity state of myosin for actin (41). Folding reactions were done either in lysate supplemented with the S30 extract or in reticulocyte lysate alone. Nascent HMM from these reactions was analyzed for its ability to bind actin in the absence of Mg2+ATP, and release from actin in the presence of Mg2+ATP (Fig. 9c). Nascent HMM produced without the extract bound actin very poorly irrespective of Mg2+ATP. In contrast, HMM from the supplemented reaction bound actin effectively in the absence of Mg2+ATP. However, the Mg2+ATP-dependent release from actin was incomplete. Native HMM, added to these reactions as an internal control, bound actin in the absence of Mg2+ATP and was released from actin in an Mg2+ATP-dependent manner (data not shown). These results suggest that the myotube cytoplasmic extract contains a factor or factors that enhance the folding of nascent HMM. The HMM formed in the presence of the extract exhibits improved folding of the myosin motor domain, stability of the S2 region, and actin binding.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Chaperonin-mediated Folding of HMM-- There has been dramatic progress in the past 10 years on the structure and function of myosin, the characterization of the motor activity, and the identification of a large number of new myosin family members (42-44). In contrast to this progress, very little is known about the myosin folding pathway. In this paper we present the first analysis of the folding of a de novo synthesized myosin subfragment, HMM. We demonstrate a folding pathway that, in a reticulocyte lysate, is mediated by CCT, yielding a dimerized molecule with associated subunits but lacking a fully folded motor domain. We further show that specific factors present in a muscle cytoplasmic extract can enhance the folding of the motor domain.

Analysis of nascent HMM by gel filtration and anion exchange chromatography and immunoprecipitation demonstrates transient association with CCT. The elution of the CCT·HMM complex on the gel filtration column is unusual considering its large mass and may suggest an interaction of the hydrophobic folding intermediate with the Superose 6 column media. The ATP-dependent release of HMM from the complex as at least two new intermediates, including a minor component with hydrodynamic properties similar to native HMM, is shown by the gel filtration analysis. The pIII intermediate behaves as an aggregate, and the association with CCT suggests that it is a partially folded species that may re-enter the folding pathway. The association of heavy and light chain subunits in all the intermediates suggests that subunit interactions are an early event in the folding pathway. Immunodepletion of CCT from the translation lysate has a dramatic effect on the recovery of the HMM heavy chain, suggesting that CCT association is a necessary step in the folding pathway.

Based on these results, we conclude that folding of HMM in rabbit reticulocyte lysate involves a cyclic reaction between HMM and CCT driven by ATP hydrolysis. In the absence of ATP, the CCT exists in a high affinity conformation for the nascent HMM molecules resulting in the formation of a CCT·HMM complex. Binding of ATP to this complex induces a low affinity conformation and releases native or partially folded HMM (21). In the analysis of the ATP-dependent release (Fig. 2), we detected disassembly of the CCT complex. Nucleotide-dependent disassembly of CCT has been reported and may represent a novel feature of this class of chaperonin (36, 37). Assembly dynamics of this type could facilitate the binding of highly asymmetric molecules like myosin by the CCT complex, thus, obviating the conceptual constraint imposed by models requiring entry of asymmetric proteins into a narrow cavity.

We investigated the role of chaperones other than CCT, in the folding of HMM. Immunoprecipitation assays showed that, in addition to CCT, nascent HMM also associates with Hsp70 (data not shown). It has been proposed that the molecular crowding inside cells necessitates a vectoral folding mechanism (45, 46). Small chaperones such as Hsp70 bind elongating nascent polypeptide chains in an extended conformation that then associate with a second chaperone such as CCT to complete the folding process. Given the large size of myosin and the discontinuous nature of its folding domains, it is likely that such a hierarchical mechanism is operative in myosin folding.

Slow Steps in the Folding Pathway and Possible Role of CCT-- The domain structure of the myosin molecule raises interesting questions concerning the rates of folding of the different parts of the molecule and the nature of its interaction with CCT. Investigation of the S2 region suggests that at least 30% of the nascent population exists as dimers. Moreover, proteolysis of nascent myosin containing a full-length heavy chain produces two stable fragments corresponding to the LMM and S2 fragments of native myosin (data not shown). Given the structural stability of an alpha -helical coiled-coil, it is likely that the S2 region in HMM and the rod in myosin fold spontaneously in solution. This notion is supported by the observation that myosin rod fragments expressed in Escherichia coli adopt a native coiled-coil conformation (6, 7).

Myosin light chains are also not good candidates for the target of the CCT. Light chains are readily expressed in bacteria and, once purified, can be exchanged into native myosin with full activity (8). Chimeric myosin containing native heavy chains and nascent light chains expressed in vitro similarly shows native properties in all our assays (data not shown), suggesting complete folding of the light chains. Furthermore, we have shown that myosin heavy and light chain subunits are found associated in all of the folding intermediates, suggesting that their association occurs early and is independent of complete heavy chain folding. In support of this, inactive myosin subfragments expressed in prokaryotic systems have been reported to undergo stoichiometric association of heavy and light chain subunits as well (9). The light chain binding domain of myosin constitutes an extended hydrophobic alpha -helix. Myosin head fragments stripped of light chains tend to aggregate around this region (47). Thus, light chain binding may be necessary to prevent aggregation of the heads during dimerization and, in a sense, light chains may be acting as chaperones.

Folding of the motor domain appears to represent the kinetic barrier in the folding pathway, whereas the S2 region and the light chains and their binding region fold efficiently. Folding analysis of the S1 subfragment, completely lacking a rod domain, shows that it also transits through intermediates similar to those of HMM (data not shown). Thus, the motor domain of HMM is the most likely target for CCT. In conjunction with this, a putative release sequence, RK(A,C,T)F, is found at or near the COOH terminus of the CCT target proteins actin and tubulin (48, 49). A homologous sequence is found at the end of the myosin catalytic domain (R708K709G710F711) just preceding the light chain binding region. This sequence is found in all striated muscle myosin II family members at this same location. The non-muscle and smooth muscle myosin II family members also have the release sequence (RKAF), but it is located in the light chain binding helix rather than at the end of the catalytic domain. The sequence is involved in the interaction of the NH2-terminal domain of the essential light chain with the myosin heavy chain, thus masking this site in non-striated myosin II family members (50). Coincidentally, these myosins have been far easier to express in heterologous expression systems (24, 50).

The core structure of the myosin catalytic domain is a nucleotide binding motif consisting of two groups of helices packed against a hydrophobic beta -sheet. This core motif is shared among the myosin and kinesin families of motor proteins and a group of G-proteins including Galpha -transducin (4). Unlike myosin, kinesin and small G-proteins (e.g. Ras) are functionally expressed in bacteria (51, 52). Myosin has large insertions extending from the core motif that distinguish it from kinesin and the small G-protein, perhaps accounting for this difference. Expression of some larger G-proteins, such as Galpha -transducin, has been difficult in bacteria, and this has been correlated with insertions into the core motif (53). Furthermore, CCT has recently been implicated in the Galpha -transducin folding pathway (21).

Effect of C2C12-S30 Fraction on the Folding of HMM-- The in vitro analyses demonstrate that CCT is a necessary, but not sufficient factor in HMM folding. To isolate other factors necessary for the complete folding of myosin, we prepared an S30 fraction from C2C12 myotubes. Folding reactions performed in the presence of the S30 extract yield significant amounts of an intermediate that behaves as a native protein in the gel filtration assay. Analysis of this species by limited proteolysis and immunological assays reveal enhanced folding of the NH2-terminal 75-kDa myosin catalytic domain and improved folding or stability of the S2 region. Significant improvement in the actin binding by nascent HMM produced in the presence of the S30 extract is also indicative of enhanced folding. Partial release of this species from actin by ATP suggests that a fraction of the population has attained a fully native conformation.

The myotube extract appears to supply factors that are missing or limiting in the reticulocyte lysate. For example, the extract may supply the right isoform of a CCT subunit that is limiting in the reticulocyte lysate. In this context, the CCT subunit TCP-1gamma is developmentally regulated in muscle cells (54). All of the CCT subunits identified so far possess conserved ATPase domains and differ from each other in the putative peptide binding domains (13). Thus, it is possible that different subunits of CCT or isoforms of TCP-1 have evolved for the folding of different proteins, and perhaps even co-evolved with the target proteins. Alternatively, additional factors acting before or after CCT may be required for complete folding of myosin as has been described for the folding of alpha  and beta  tubulin (55-57).

Currently, there is wide speculation regarding the range of substrates for CCT. Discovery of new targets for this chaperonin will certainly improve our understanding of the general mechanism of chaperonin-mediated protein folding in vivo. The unique structure of myosin also raises important questions concerning its interaction with the chaperonin, and the hierarchy of events during folding. The investigation of the folding pathway in vivo and the isolation and purification of the folding factors from muscle extracts are necessary for a complete description of the myosin II folding pathway.

    ACKNOWLEDGEMENTS

We acknowledge the assistance of Fumi Kinose, Soojin Kwon, and Heather Neenhold in this work. We are indebted to Dr. Carole L. Moncman for advice and critical reading of this manuscript.

    FOOTNOTES

* This work was supported by United States Public Health Service Grant AR38454 (to D. A. W.), a postdoctoral fellowship from the American Heart Association-New Jersey Affiliate (to R. S.), and a grant from the Foundation of the University of Medicine and Dentistry of New Jersey (to R. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Pathology and Laboratory Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, 675 Hoes Ln., Piscataway, NJ 08854. Tel.: 732-235-4759; Fax: 732-235-4825.

    ABBREVIATIONS

The abbreviations used are: S1, myosin subfragment 1; CCT, chaperonin containing TCP-1; F-actin, filamentous actin; HMM, heavy meromyosin; LC2 and LC3, myosin light chains 2 and 3; LMM, light meromyosin; mAb, monoclonal antibody; S2, myosin subfragment-2; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; ATPgamma S, adenosine 5'-O-(thiotriphosphate); MES, 4-morpholineethanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Lowey, S. (1994) in Myology (Engel, A. G. , and Franzini-Armstrong, C., eds) , pp. 485-505, McGraw-Hill Book Co., New York
2. Rayment, I., Holden, H. M., Whittaker, M., Yohn, C. B., Lorenz, M., Holmes, K. C., and Milligan, R. A. (1993) Science 261, 58-65[Abstract/Free Full Text]
3. Rayment, I., Rypniewski, W. R., Schmidt-Base, K., Smith, R., Tomchick, D. R., Benning, M. M., Winkelmann, D. A., Wesenberg, G., and Holden, H. M. (1993) Science 261, 50-58[Abstract/Free Full Text]
4. Vale, R. (1996) J. Cell Biol. 135, 291-301[Free Full Text]
5. Spudich, J. A. (1994) Nature 372, 515-518[CrossRef][Medline] [Order article via Infotrieve]
6. De Lozanne, A., Berlot, C. H., Leinwand, L. A., and Spudich, J. A. (1987) J. Cell Biol. 105, 2999-3005[Abstract/Free Full Text]
7. Atkinson, S. J., and Stewart, M. (1991) J. Cell Sci. 99, 823-836[Abstract]
8. Wolff-Long, V. L., Saraswat, L. D., and Lowey, S. (1993) J. Biol. Chem. 268, 23162-23167[Abstract/Free Full Text]
9. McNally, E. M., Goodwin, E. B., Spudich, J. A., and Leinwand, L. A. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7270-7273[Abstract/Free Full Text]
10. Gething, M. J., and Sambrook, J. (1992) Nature 355, 33-45[CrossRef][Medline] [Order article via Infotrieve]
11. Hendrick, J. P., and Hartl, F. U. (1995) FASEB J. 9, 1559-1569[Abstract]
12. Hartl, F. U. (1996) Nature 381, 571-579[CrossRef][Medline] [Order article via Infotrieve]
13. Kubota, H., Hynes, G., and Willison, K. (1995) Eur. J. Biochem. 230, 3-16[Medline] [Order article via Infotrieve]
14. Gao, Y., Thomas, J. O., Chow, R. L., Lee, G. H., and Cowan, N. J. (1992) Cell 69, 1043-1050[CrossRef][Medline] [Order article via Infotrieve]
15. Frydman, J., Nimmesgern, E., Erdjument-Bromage, H., Wall, J. S., Tempst, P., and Hartl, F. U. (1992) EMBO J. 11, 4767-4778[Medline] [Order article via Infotrieve]
16. Yaffe, M. B., Farr, G. W., Miklos, D., Horwich, A. L., Sternlicht, M. L., and Sternlicht, H. (1992) Nature 358, 245-248[CrossRef][Medline] [Order article via Infotrieve]
17. Sternlicht, H., Farr, G. W., Sternlicht, M. L., Driscoll, J. K., Willison, K., and Yaffe, M. B. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9422-9426[Abstract/Free Full Text]
18. Melki, R., Vainberg, I. E., Chow, R. L., and Cowan, N. J. (1993) J. Cell Biol. 122, 1301-1310[Abstract/Free Full Text]
19. Lewis, S. A., Tian, G., Vainberg, I. E., and Cowan, N. J. (1996) J. Cell Biol. 132, 1-4[Free Full Text]
20. Vainberg, I. E., Lewis, S. A., Rommelaere, H., Ampe, C., Vandekerckhove, J., Klein, H. L., and Cowan, N. J. (1998) Cell 93, 863-873[CrossRef][Medline] [Order article via Infotrieve]
21. Farr, G. W., Scharl, E. C., Schumacher, R. J., Sondek, S., and Horwich, A. L. (1997) Cell 89, 927-937[CrossRef][Medline] [Order article via Infotrieve]
22. Netzer, W. J., and Hartl, F. U. (1997) Nature 388, 343-349[CrossRef][Medline] [Order article via Infotrieve]
23. Spudich, J. A. (1989) Cell Regul. 1, 1-11[Medline] [Order article via Infotrieve]
24. Trybus, K. M. (1994) J. Biol. Chem. 269, 20819-20822[Abstract/Free Full Text]
25. Sweeney, H. L., Straceski, A. J., Leinwand, L. A., Tikunov, B. A., and Faust, L. (1994) J. Biol. Chem. 269, 1603-1605[Abstract/Free Full Text]
26. Kinose, F., Wang, S. X., Kidambi, U. S., Moncman, C. L., and Winkelmann, D. A. (1996) J. Cell Biol. 134, 895-909[Abstract/Free Full Text]
27. Reinach, F. C., and Fischman, D. A. (1985) J. Mol. Biol. 181, 411-422[CrossRef][Medline] [Order article via Infotrieve]
28. Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve]
29. Kyhse-Andersen, J. (1984) J. Biochem. Biophys. Methods 10, 203-209[CrossRef][Medline] [Order article via Infotrieve]
30. Willison, K., Lewis, V., Zuckerman, K. S., Cordell, J., Dean, C., Miller, K., Lyon, M. F., and Marsh, M. (1989) Cell 57, 621-632[CrossRef][Medline] [Order article via Infotrieve]
31. Winkelmann, D. A., and Lowey, S. (1986) J. Mol. Biol. 188, 595-612[CrossRef][Medline] [Order article via Infotrieve]
32. Moldave, K., and Fischer, I. (1983) Methods Enzymol. 101, 629-635[Medline] [Order article via Infotrieve]
33. Jackson, R. J., and Hunt, T. (1983) Methods Enzymol. 96, 50-74[Medline] [Order article via Infotrieve]
34. Margossian, S. S., and Lowey, S. (1982) Methods Enzymol. 85, 55-71
35. Winkelmann, D. A., Kinose, F., and Chung, A. L. (1993) J. Muscle Res. Cell Motil. 14, 452-467[CrossRef][Medline] [Order article via Infotrieve]
36. Liou, A. K., McCormack, E. A., and Willison, K. R. (1998) Biol. Chem. 379, 311-319[Medline] [Order article via Infotrieve]
37. Roobol, A., and Carden, M. J. (1999) Eur J. Cell Biol. 78, 21-32[Medline] [Order article via Infotrieve]
38. Mornet, D., Bonet, A., Audemard, E., and Bonicel, J. (1989) J. Muscle Res. Cell Motil. 10, 10-24[CrossRef][Medline] [Order article via Infotrieve]
39. Winkelmann, D. A., Bourdieu, L., Ott, A., Kinose, F., and Libchaber, A. (1995) Biophys. J. 68, 2444-2453[Abstract/Free Full Text]
40. Moncman, C. L., Rindt, H., Robbins, J., and Winkelmann, D. A. (1993) Mol. Biol. Cell 4, 1051-1067[Abstract]
41. Huxley, H. E. (1973) Nature 243, 445-449[CrossRef][Medline] [Order article via Infotrieve]